(Q34339471)

1 August 2017

title

HIV treatment as prevention: modelling the cost of antiretroviral treatment--state of the art and future directions (English)

1 reference

1 August 2017

main subject

anti-retroviral agent

0 references

prevention of HIV/AIDS

0 references

Gesine Meyer-Rath

1

0 references

author name string

Mead Over

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

10 July 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

9

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

e1001247

1 reference

Creative Commons Attribution 4.0 International

1 August 2017

copyright license

start time

10 July 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Rates and cost of hospitalization before and after initiation of antiretroviral therapy in urban and rural settings in South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

HIV treatment as prevention: natural experiments highlight limits of antiretroviral treatment as HIV prevention

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

HIV treatment as prevention: issues in economic evaluation

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Economic returns to investment in AIDS treatment in low and middle income countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Prevention of HIV-1 infection with early antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Long-term costs and health impact of continued global fund support for antiretroviral therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The cost of providing comprehensive HIV treatment in PEPFAR-supported programs

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The quality of medical advice in low-income countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

A cost function for HIV prevention services: is there a 'u' - shape?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The economics of effective AIDS treatment in Thailand

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Long-term experience providing antiretroviral drugs in a fee-for-service HIV clinic in Uganda: evidence of extended virologic and CD4+ cell count responses

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Accounting for the cost of scaling-up health interventions

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

AIDS. Resource needs for HIV/AIDS.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The cost of HIV treatment and care. A global review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Defining and refining international donor support for combating the AIDS pandemic

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Combined antiviral treatment in HIV infection. Is it value for money?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Health economics in HIV disease. A review of the European literature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/microliters in 5 European countries

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost of medication therapy in ambulatory HIV-infected patients.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost effectiveness analysis of early zidovudine treatment of HIV infected patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost Effectiveness of Low-Dose Zidovudine Therapy for Asymptomatic Patients with Human Immunodeficiency Virus (HIV) Infection

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3393674

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

6 July 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

The cost-effectiveness of triple nucleoside analogue therapy antiretroviral regimens in the treatment of HIV in the United Kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

The cost effectiveness of combination antiretroviral therapy for HIV disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

One world, one hope: the cost of providing antiretroviral therapy to all nations

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Towards an improved investment approach for an effective response to HIV/AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Professionalism and the know-do gap: exploring intrinsic motivation among health workers in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Modelling the Cost Effectiveness of Lamivudine/Zidovudine Combination Therapy in HIV Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Assessing the cost-effectiveness of HAART for adults with HIV in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Modeling the Long-Term Outcomes and Costs of HIV Antiretroviral Therapy Using HIV RNA Levels: Application to a Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

The high cost of medical care for patients who present late (CD4<200 cells/muL) with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Cost-Effectiveness of Earlier Initiation of Antiretroviral Therapy for Uninsured HIV-Infected Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1001247

Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen

21 January 2018

1 reference

12 December 2020

Pricing of drugs and donations: options for sustainable equity pricing

1 reference

12 December 2020

Cost and cost-effectiveness of antiretroviral therapy for HIV infection in Singapore

1 reference

12 December 2020

Health and federal budgetary effects of increasing access to antiretroviral medications for HIV by expanding Medicaid

1 reference

12 December 2020

Costs of eliminating HIV in South Africa have been underestimated

1 reference

12 December 2020

Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world

1 reference

12 December 2020

Modeling the use of triple combination therapy in five countries: nevirapine, Zidovudine, and Didanosine

1 reference

12 December 2020

Combination antiretroviral therapy in HIV infection. An economic perspective

1 reference

12 December 2020

10.1371/JOURNAL.PMED.1001247

Identifiers

DOI

1 reference

1 August 2017

1 reference

1 August 2017

1 reference